WO2007146802A3 - System and compositions for isolating suppressors of hiv-1 protease - Google Patents

System and compositions for isolating suppressors of hiv-1 protease Download PDF

Info

Publication number
WO2007146802A3
WO2007146802A3 PCT/US2007/070757 US2007070757W WO2007146802A3 WO 2007146802 A3 WO2007146802 A3 WO 2007146802A3 US 2007070757 W US2007070757 W US 2007070757W WO 2007146802 A3 WO2007146802 A3 WO 2007146802A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease
hiv
suppressors
isolating
compositions
Prior art date
Application number
PCT/US2007/070757
Other languages
French (fr)
Other versions
WO2007146802A2 (en
Inventor
Richard Y Zhao
Robert T Elder
Original Assignee
Univ Maryland
Richard Y Zhao
Robert T Elder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland, Richard Y Zhao, Robert T Elder filed Critical Univ Maryland
Publication of WO2007146802A2 publication Critical patent/WO2007146802A2/en
Publication of WO2007146802A3 publication Critical patent/WO2007146802A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a yeast screening assay for the identification of suppressors of a protease, such as the HIV-I protease and/or HIV-2 protease, for example. Upon overexpression of HIV-I protease in Schizosaccharomyces pombe, for example, the cell dies, but in the presence of a candidate inhibitor with protease suppressor activity, the cell lives, thereby providing an assay for the identification of one or more suppressors. In additional aspects, there is an in vivo protease activity screen, used alternatively or additionally to a viability screen, such as for cleavage of a HIV-I protease-specific site. In further aspects, the suppressor is employed for the treatment of an individual infected with HIV virus or with AIDS.
PCT/US2007/070757 2006-06-09 2007-06-08 System and compositions for isolating suppressors of hiv-1 protease WO2007146802A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81268506P 2006-06-09 2006-06-09
US60/812,685 2006-06-09

Publications (2)

Publication Number Publication Date
WO2007146802A2 WO2007146802A2 (en) 2007-12-21
WO2007146802A3 true WO2007146802A3 (en) 2008-06-26

Family

ID=38832714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/070757 WO2007146802A2 (en) 2006-06-09 2007-06-08 System and compositions for isolating suppressors of hiv-1 protease

Country Status (2)

Country Link
CN (1) CN101501210A (en)
WO (1) WO2007146802A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117088988B (en) * 2023-10-20 2024-02-06 浙江迪福润丝生物科技有限公司 Fusion protein, plasmid and application thereof in HIV protease inhibitor screening and drug effect evaluation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627043A (en) * 1993-07-07 1997-05-06 The Regents Of The University Of Colorado Yeast strains used to identify inhibitors of dibasic amino acid processing endoproteases
US6001553A (en) * 1994-04-26 1999-12-14 Cadus Pharmaceutical Corporation Functional expression of mammalian adenylyl cyclase in yeast
USH1892H (en) * 1995-07-27 2000-10-03 Pharmacia And Upjohn Company High volume nutrient based yeast two-hybrid assay for the identification of specific protein:protein interacting inhibitors
US20020061313A1 (en) * 1997-04-04 2002-05-23 The Board Of Supervisors Of Louisiana State University Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor
WO2003062263A2 (en) * 2002-01-16 2003-07-31 Ortho Mc Neil Pharmaceutical, Inc. Aggrecanase-1 and -2 peptide substrates and methods
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US20050244819A1 (en) * 2004-03-15 2005-11-03 Keck Graduate Institute Assay system for screening protease inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627043A (en) * 1993-07-07 1997-05-06 The Regents Of The University Of Colorado Yeast strains used to identify inhibitors of dibasic amino acid processing endoproteases
US6001553A (en) * 1994-04-26 1999-12-14 Cadus Pharmaceutical Corporation Functional expression of mammalian adenylyl cyclase in yeast
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
USH1892H (en) * 1995-07-27 2000-10-03 Pharmacia And Upjohn Company High volume nutrient based yeast two-hybrid assay for the identification of specific protein:protein interacting inhibitors
US20020061313A1 (en) * 1997-04-04 2002-05-23 The Board Of Supervisors Of Louisiana State University Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor
WO2003062263A2 (en) * 2002-01-16 2003-07-31 Ortho Mc Neil Pharmaceutical, Inc. Aggrecanase-1 and -2 peptide substrates and methods
US20050244819A1 (en) * 2004-03-15 2005-11-03 Keck Graduate Institute Assay system for screening protease inhibitors

Also Published As

Publication number Publication date
CN101501210A (en) 2009-08-05
WO2007146802A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
Gomes et al. Cathepsin L in COVID-19: from pharmacological evidences to genetics
Arenaccio et al. Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef-and ADAM17-dependent mechanism
HK1115192A1 (en) Methods and compositions for diagnosis and treatment of influenza
WO2005115398A3 (en) Hiv integrase inhibitors
CA2668898C (en) Surfactant thickened systems comprising microfibrous cellulose and methods of making same
BRPI0612409B8 (en) peroxycarboxylic acid based surfactant compositions and method of reducing the population of microorganisms on an object
HK1062029A1 (en) Multiplication of viruses in a cell culture
CL2008003405A1 (en) Compounds derived from thienopyridine, inhibitors of the hiv integrase enzyme; pharmaceutical composition comprising said compounds; and its use to treat an HIV infection.
Tabtieng et al. Caspase-dependent suppression of type I interferon signaling promotes Kaposi's sarcoma-associated herpesvirus lytic replication
WO2008088747A3 (en) Method of monitoring hiv infection
MX344371B (en) Signal amplification.
WO2010122367A3 (en) Meganuclease variants cleaving the genomic insertion of a virus and uses thereof
MY137777A (en) Inhibitors of aspartyl protease
WO2007053831A3 (en) Optimum nonlinear correntropy filter
WO2021159020A3 (en) Compositions and methods for detection of coronavirus
Cordeiro et al. The HIV aspartyl protease inhibitor ritonavir impairs planktonic growth, biofilm formation and proteolytic activity in Trichosporon spp.
WO2007146802A3 (en) System and compositions for isolating suppressors of hiv-1 protease
TW200745344A (en) Improved extraction methods and assays for feed enzymes
WO2010129485A3 (en) Compositions and methods for identifying enzyme and transport protein inhibitors
CL2012002743A1 (en) Combination comprising Maraviroc, a hiv-1 protease inhibitor and a pharmacokinetic enhancer, use in the preparation of a medicament useful in the treatment of HIV infection.
WO2008045017A3 (en) Sars and ebola inhibitors and use thereof, and methods for their discovery
WO2007002172A3 (en) Hiv-1 protease inhibitors
WO2007018550A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection
WO2009126517A3 (en) Optimized probes and primers and methods of using same for the detection, quantification and grouping of hiv-1
EA200600560A1 (en) HIV VIRUS PREVENTION INHIBITORS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780029436.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07798310

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07798310

Country of ref document: EP

Kind code of ref document: A2